J&J Buys Up Ambrx for $2B - San Diego Business Journal sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.
B. Riley downgraded shares of Ambrx Biopharma (NYSE:AMAM – Free Report) from a buy rating to a neutral rating in a research report report published on Tuesday, Marketbeat Ratings reports. B. Riley currently has $28.00 price objective on the stock, up from their previous price objective of $26.00. Several other brokerages have also recently commented […]
Johnson & Johnson agreed to acquire Ambrx Biopharma, which is developing cancer treatments. The biotech was spun out from The Scripps Research Institute in 2003.
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.